Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) FCF Margin: 2009-2025

Historic FCF Margin for Northwest Biotherapeutics (NWBO) over the last 17 years, with Sep 2025 value amounting to -7,047.50%.

  • Northwest Biotherapeutics' FCF Margin fell 469204.00% to -7,047.50% in Q3 2025 from the same period last year, while for Sep 2025 it was -5,427.64%, marking a year-over-year decrease of 197225.00%. This contributed to the annual value of -4,199.06% for FY2024, which is 124492.00% down from last year.
  • According to the latest figures from Q3 2025, Northwest Biotherapeutics' FCF Margin is -7,047.50%, which was down 32.04% from -5,337.40% recorded in Q2 2025.
  • Northwest Biotherapeutics' 5-year FCF Margin high stood at 1,110.06% for Q4 2021, and its period low was -8,770.13% during Q4 2024.
  • Its 3-year average for FCF Margin is -4,454.53%, with a median of -3,904.72% in 2023.
  • Per our database at Business Quant, Northwest Biotherapeutics' FCF Margin soared by 37,665,505bps in 2021 and then tumbled by 518,568bps in 2022.
  • Northwest Biotherapeutics' FCF Margin (Quarterly) stood at 1,110.06% in 2021, then crashed by 295,411bps to -1,844.05% in 2022, then tumbled by 206,067bps to -3,904.72% in 2023, then crashed by 486,541bps to -8,770.13% in 2024, then crashed by 469,204bps to -7,047.50% in 2025.
  • Its FCF Margin stands at -7,047.50% for Q3 2025, versus -5,337.40% for Q2 2025 and -2,536.27% for Q1 2025.